Effects of Secretin on the Normal and Pathologicalβ-Cell*
Authors:
- Benjamin GlaserBGBenjamin Glaser
- Brahm ShapiroBSBrahm Shapiro
- Jerry GlowniakJGJerry Glowniak
- Stefan S. FajansSFStefan S. Fajans
- Aaron I. VinikAVAaron I. Vinik
- 1 June 1988
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 66 (6) , 1138-1143
Abstract
Secretin is a gastrointestinal hormone that stimulates insulin secretion and enhances the insulin response to glucose. The mechanism by which secretin acts on the beta-cell has not been extensively studied. The plasma insulin responses to secretin (2 U/kg), expressed as the percent increase relative to basal plasma insulin concentrations, were similar in normal (n = 23) and obese subjects with normal glucose tolerance (n = 12), but were decreased in obese subjects with abnormal glucose tolerance (n = 11). The insulin response to secretin was directly proportional to the basal insulin concentration in these three groups. The effects of secretin on beta-cell function was not altered by propranolol (n = 6), atropine (n = 8), or surgical vagotomy (n = 10). Patients with single islet cell tumors secreting insulin (n = 18) had no plasma insulin response to secretin, whereas patients with noninsulin-secreting pancreatic tumors (gastrinomas; n = 6) and patients in whom single insulinomas had been removed (n = 7) responded normally. Two adult patients with multiple B-cell adenomas and hyperplasia (not associated with multiple endocrine neoplasia type I) hyperresponded to secretin, whereas patients with multiple endocrine neoplasia, type I, without hyperinsulinism responded normally. One patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia. These data suggest that secretin stimulates beta-cells directly rather than through cholinergic, adrenergic, or vagal peptidergic neural mechanisms. In addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia. The lack of a plasma insulin response in patients with single insulinomas and the high normal or exaggerated response in patients with multiple B-cell adenomas and hyperplasia may prove useful in differentiating these entities.Keywords
This publication has 12 references indexed in Scilit:
- Plasma Human Pancreatic Polypeptide Responses to Administered Secretin: Effects of Surgical Vagotomy, Cholinergic Blockade, and Chronic Pancreatitis*The Journal of Clinical Endocrinology & Metabolism, 1980
- Impaired Pancreatic Polypeptide Responses to Insulin-Induced Hypoglycemia in Diabetic Autonomic Neuropathy*The Journal of Clinical Endocrinology & Metabolism, 1980
- Effects of cholecystokinin, secretin, and pancreatic polypeptide on secretion of gastric inhibitory polypeptide, insulin, and glucagonLife Sciences, 1979
- Influence of the vagus nerve on release and action of secretin in dog.The Journal of Physiology, 1979
- Plasma secretin concentrations in fasting and postprandial states in dog.American Journal of Physiology-Endocrinology and Metabolism, 1979
- The Augmentation Effect of Secretin on the Insulin Responses to Known Stimuli: Specificity for GlucoseThe Journal of Clinical Endocrinology & Metabolism, 1977
- Insulin, Proinsulin, Glucagon and Gastrin in Pancreatic Tumors and in Plasma of Patients with Organic Hyperinsulinism1The Journal of Clinical Endocrinology & Metabolism, 1977
- THE EFFECT OF ATROPINE ON THE INSULIN RELEASE CAUSED BY ORAL AND INTRAVENOUS GLUCOSE IN HUMAN SUBJECTSEuropean Journal of Endocrinology, 1976
- SECRETIN-INDUCED INSULIN RESPONSEEuropean Journal of Endocrinology, 1976
- The Effects of Secretin, Pancreozymin, and Gastrin on Insulin and Glucagon Secretion in Anesthetized Dogs *Journal of Clinical Investigation, 1967